1.
Baseline characteristics and clinical factors of HCC patients in this study
| Variables | Overall (n=89) | Low Ki-67 (n=40) | High Ki-67 (n=49) | P |
| HCC, hepatocellular carcinoma; AFP, alpha-fetoprotein; HBsAg, hepatitis B surface antigen; A-HCV, hepatitis C antibody; BCLC, Barcelona-Clinic Liver Cancer; APHE, arterial phase hyperenhancement; HBP, hepatobiliary phase. | ||||
Age (
) (year)
|
50.72±11.40 | 52.93±9.93 | 48.92±12.28 | 0.099 |
| Sex (male/female) | 68/21 | 31/9 | 37/12 | 0.826 |
| Size (cm) | 5.86±2.74 | 5.68±2.31 | 6.02±3.06 | 0.550 |
| AFP (ng/mL) | 0.020 | |||
| ≤20 | 37 | 22 | 15 | |
| >20 | 52 | 18 | 34 | |
| HBsAg/A-HCV | 0.199 | |||
| Positive | 74 | 31 | 43 | |
| Negative | 15 | 9 | 6 | |
| BCLC-stage | 0.012 | |||
| 0 | 0 | 0 | 0 | |
| A | 18 | 6 | 12 | |
| B | 52 | 30 | 22 | |
| C | 19 | 4 | 15 | |
| Cirrhosis | 0.941 | |||
| Absent | 56 | 25 | 31 | |
| Present | 33 | 15 | 18 | |
| Multifocality | 0.391 | |||
| Absent | 65 | 31 | 34 | |
| Present | 24 | 9 | 15 | |
| APHE | 0.317 | |||
| Absent | 3 | 0 | 3 | |
| Present | 86 | 40 | 46 | |
| Washout | 1.000 | |||
| Absent | 5 | 2 | 3 | |
| Present | 84 | 38 | 46 | |
| Capsule integrity | 0.042 | |||
| Complete | 22 | 14 | 8 | |
| Incomplete | 67 | 26 | 41 | |
| Internal arteries | 0.278 | |||
| Absent | 50 | 25 | 25 | |
| Present | 39 | 15 | 24 | |
| Tumor margin | 0.009 | |||
| Smooth | 66 | 35 | 31 | |
| Non-smooth | 23 | 5 | 18 | |
| Enhancing capsule | 0.043 | |||
| Absent | 26 | 16 | 10 | |
| Present | 63 | 24 | 39 | |
| HBP peritumoral hypointense halo | 0.816 | |||
| Absent | 30 | 14 | 16 | |
| Present | 59 | 26 | 33 | |